Annual CFF
$41.00 K
-$76.91 M-99.95%
December 31, 2023
Summary
- As of February 12, 2025, EIGR annual cash flow from financing activities is $41.00 thousand, with the most recent change of -$76.91 million (-99.95%) on December 31, 2023.
- During the last 3 years, EIGR annual CFF has fallen by -$97.42 million (-99.96%).
- EIGR annual CFF is now -99.96% below its all-time high of $100.98 million, reached on December 31, 2018.
Performance
EIGR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$7000.00
-$8000.00-53.33%
December 31, 2023
Summary
- As of February 12, 2025, EIGR quarterly cash flow from financing activities is $7000.00, with the most recent change of -$8000.00 (-53.33%) on December 31, 2023.
- Over the past year, EIGR quarterly CFF has increased by +$67.00 thousand (+111.67%).
- EIGR quarterly CFF is now -99.99% below its all-time high of $53.26 million, reached on June 30, 2019.
Performance
EIGR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$41.00 K
+$67.00 K+257.69%
December 31, 2023
Summary
- As of February 12, 2025, EIGR TTM cash flow from financing activities is $41.00 thousand, with the most recent change of +$67.00 thousand (+257.69%) on December 31, 2023.
- Over the past year, EIGR TTM CFF has dropped by -$76.91 million (-99.95%).
- EIGR TTM CFF is now -99.96% below its all-time high of $110.25 million, reached on June 30, 2019.
Performance
EIGR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
EIGR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -100.0% | +111.7% | -100.0% |
| 3 y3 years | -100.0% | -100.0% | -100.0% |
| 5 y5 years | -100.0% | -100.0% | -99.9% |
EIGR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.0% | at low | -100.0% | +108.0% | -100.0% | +131.8% |
| 5 y | 5-year | -100.0% | at low | -100.0% | +108.0% | -100.0% | +131.8% |
| alltime | all time | -100.0% | +106.9% | -100.0% | +100.1% | -100.0% | +100.4% |
Eiger BioPharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $41.00 K(-99.9%) | $7000.00(-53.3%) | $41.00 K(-257.7%) |
| Sep 2023 | - | $15.00 K(-168.2%) | -$26.00 K(-79.8%) |
| Jun 2023 | - | -$22.00 K(-153.7%) | -$129.00 K(-100.4%) |
| Mar 2023 | - | $41.00 K(-168.3%) | $31.19 M(-59.5%) |
| Dec 2022 | $76.95 M(+2329.9%) | -$60.00 K(-31.8%) | $76.95 M(-3.9%) |
| Sep 2022 | - | -$88.00 K(-100.3%) | $80.08 M(-0.3%) |
| Jun 2022 | - | $31.30 M(-31.7%) | $80.33 M(+64.1%) |
| Mar 2022 | - | $45.80 M(+1394.8%) | $48.95 M(+1445.8%) |
| Dec 2021 | $3.17 M(-96.8%) | $3.06 M(+1815.0%) | $3.17 M(-83.7%) |
| Sep 2021 | - | $160.00 K(-322.2%) | $19.46 M(-71.4%) |
| Jun 2021 | - | -$72.00 K(-580.0%) | $68.01 M(-30.0%) |
| Mar 2021 | - | $15.00 K(-99.9%) | $97.13 M(-0.3%) |
| Dec 2020 | $97.46 M(+67.5%) | $19.35 M(-60.3%) | $97.46 M(+24.3%) |
| Sep 2020 | - | $48.72 M(+67.7%) | $78.43 M(+160.0%) |
| Jun 2020 | - | $29.05 M(+8344.5%) | $30.16 M(-44.5%) |
| Mar 2020 | - | $344.00 K(+7.8%) | $54.37 M(-6.6%) |
| Dec 2019 | $58.20 M(-42.4%) | $319.00 K(-29.1%) | $58.20 M(-44.9%) |
| Sep 2019 | - | $450.00 K(-99.2%) | $105.64 M(-4.2%) |
| Jun 2019 | - | $53.26 M(+1176.8%) | $110.25 M(+4.9%) |
| Mar 2019 | - | $4.17 M(-91.3%) | $105.12 M(+4.1%) |
| Dec 2018 | $100.98 M | $47.77 M(+843.8%) | $100.98 M(+38.2%) |
| Sep 2018 | - | $5.06 M(-89.5%) | $73.06 M(+7.3%) |
| Jun 2018 | - | $48.12 M(>+9900.0%) | $68.09 M(+241.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $34.00 K(-99.8%) | $19.97 M(-0.1%) |
| Dec 2017 | $19.99 M(-69.3%) | $19.84 M(>+9900.0%) | $19.99 M(+34.1%) |
| Sep 2017 | - | $96.00 K(>+9900.0%) | $14.91 M(-54.9%) |
| Jun 2017 | - | $0.00(-100.0%) | $33.05 M(-0.1%) |
| Mar 2017 | - | $57.00 K(-99.6%) | $33.08 M(-49.2%) |
| Dec 2016 | $65.14 M(+394.2%) | $14.76 M(-19.0%) | $65.14 M(-12.6%) |
| Sep 2016 | - | $18.23 M(>+9900.0%) | $74.54 M(+67.3%) |
| Jun 2016 | - | $32.00 K(-99.9%) | $44.55 M(-0.3%) |
| Mar 2016 | - | $32.12 M(+33.0%) | $44.67 M(+238.9%) |
| Dec 2015 | $13.18 M(-86.4%) | $24.16 M(-305.4%) | $13.18 M(-221.5%) |
| Sep 2015 | - | -$11.76 M(-8101.4%) | -$10.85 M(-121.0%) |
| Jun 2015 | - | $147.00 K(-76.9%) | $51.61 M(+0.1%) |
| Mar 2015 | - | $636.00 K(+385.5%) | $51.58 M(-46.8%) |
| Dec 2014 | $96.98 M(<-9900.0%) | $131.00 K(-99.7%) | $96.98 M(+0.1%) |
| Sep 2014 | - | $50.69 M(>+9900.0%) | $96.93 M(+112.8%) |
| Jun 2014 | - | $121.00 K(-99.7%) | $45.56 M(+0.3%) |
| Mar 2014 | - | $46.03 M(>+9900.0%) | $45.44 M(-7723.7%) |
| Dec 2013 | -$596.00 K(-101.2%) | $81.00 K(-112.0%) | -$596.00 K(-12.0%) |
| Sep 2013 | - | -$677.00 K(<-9900.0%) | -$677.00 K(<-9900.0%) |
| Jun 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | $49.84 M(+3337.4%) | - | - |
| Dec 2011 | $1.45 M(-67.6%) | - | - |
| Jun 2011 | $4.47 M | - | - |
FAQ
- What is Eiger BioPharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Eiger BioPharmaceuticals?
- What is Eiger BioPharmaceuticals annual CFF year-on-year change?
- What is Eiger BioPharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Eiger BioPharmaceuticals?
- What is Eiger BioPharmaceuticals quarterly CFF year-on-year change?
- What is Eiger BioPharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Eiger BioPharmaceuticals?
- What is Eiger BioPharmaceuticals TTM CFF year-on-year change?
What is Eiger BioPharmaceuticals annual cash flow from financing activities?
The current annual CFF of EIGR is $41.00 K
What is the all time high annual CFF for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals all-time high annual cash flow from financing activities is $100.98 M
What is Eiger BioPharmaceuticals annual CFF year-on-year change?
Over the past year, EIGR annual cash flow from financing activities has changed by -$76.91 M (-99.95%)
What is Eiger BioPharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of EIGR is $7000.00
What is the all time high quarterly CFF for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals all-time high quarterly cash flow from financing activities is $53.26 M
What is Eiger BioPharmaceuticals quarterly CFF year-on-year change?
Over the past year, EIGR quarterly cash flow from financing activities has changed by +$67.00 K (+111.67%)
What is Eiger BioPharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of EIGR is $41.00 K
What is the all time high TTM CFF for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals all-time high TTM cash flow from financing activities is $110.25 M
What is Eiger BioPharmaceuticals TTM CFF year-on-year change?
Over the past year, EIGR TTM cash flow from financing activities has changed by -$76.91 M (-99.95%)